無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

膵臓性キニノゲナーゼの中国市場分析・予測

Investigation Report on China's Pancreatic Kininogenase Market, 2018-2022

発行 China Research and Intelligence 商品コード 762939
出版日 ページ情報 英文 30 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.39円で換算しております。
Back to Top
膵臓性キニノゲナーゼの中国市場分析・予測 Investigation Report on China's Pancreatic Kininogenase Market, 2018-2022
出版日: 2019年01月01日 ページ情報: 英文 30 Pages
概要

当レポートでは、中国の膵臓性キニノゲナーゼ市場について調査分析し、状況、市場規模、主要メーカー、市場競合、小売価格、市場の見通しについて、体系的な情報を提供しています。

第1章 膵臓性キニノゲナーゼの関連概念

  • 膵臓性キニノゲナーゼの適応
  • 中国における膵臓性キニノゲナーゼ開発の歴史
  • 中国における膵臓性キニノゲナーゼの政府承認

第2章 中国における膵臓性キニノゲナーゼの売上

  • 売上額
    • 総売上額
    • 売上額:地域別
  • 売上高
    • 総売上高
    • 売上高:地域別
  • 売上:剤形別
    • 注射
    • タブレット

第3章 中国における膵臓性キニノゲナーゼ主要メーカーの分析

  • 主要メーカーの市場シェア分析
  • Shanghai Livzon Pharmaceutical Co., Ltd.
  • Sichuan Shunsheng Pharmaceutical Co., Ltd.
  • Changzhou Qianhong Bio-pharma Co., Ltd.
  • Chengdu Tongde Pharmaceutical Co., Ltd.
  • Henan Livu Pharmaceutical Co., Ltd.

第4章 中国における膵臓性キニノゲナーゼの価格

  • Shanghai Livzon Pharmaceutical Co., Ltd. (Guangle)
  • Sichuan Shunsheng Pharmaceutical Co., Ltd. (Dashun)
  • Changzhou Qianhong Bio-pharma Co., Ltd. (Yikai)
  • Chengdu Tongde Pharmaceutical Co., Ltd. (Tongde)
  • Henan Livu Pharmaceutical Co., Ltd. (Duomeile)

第5章 中国における膵臓性キニノゲナーゼ市場の見通し

  • 市場発展に影響を与える要因の分析
  • 市場規模の予測
  • 市場動向の予測
目次
Product Code: 1901367

The incidence of and the death rate from cardiovascular and cerebrovascular diseases are increasing in China with the development of economy, the change of lifestyle and the aging of the population. It is estimated that nearly 300 million people in China are suffering from cardiovascular and cerebrovascular diseases. The number of patients with stroke, coronary heart disease, heart failure, pulmonary heart disease, rheumatic heart disease, congenital heart disease and hypertension amounts to 13 million, 11 million, 4.5 million, 5 million, 2.5 million, 2 million and 270 million respectively. With a higher death rate than tumors and other diseases, cardiovascular diseases account for more than 40% disease deaths in China. In particular, rural areas have seen higher death rate from cardiovascular diseases than urban areas in recent years. And the costs of hospitalization resulting from cardiovascular and cerebrovascular diseases are also increasing sharply.

Pancreatic Kininogenase can be used to treat cardiovascular and cerebrovascular diseases such as primary hypertension, arteriosclerosis, coronary atherosclerotic heart disease, cerebral arteriosclerosis, cerebral thrombosis, retinal vascular disorder and peripheral vascular disease. Recent studies have found that Pancreatic Kininogenase can also be used to prevent diabetic microangiopathy and early diabetic nephropathy by reducing the discharge of urinary albumin. In addition, Pancreatic Kininogenase can increase the activity and production of sperms, and thus has certain curative effect on male infertility, according to domestic clinical data.

In 1999, Changzhou Qianhong Bio-pharma Co., Ltd.'s Pancreatic Kininogenase was first launched in China, followed by the counterparts of Chengdu Tongde Pharmaceutical Co., Ltd., Henan Livu Pharmacy Co., Ltd., Shanghai Livzon Pharmaceutical Co., Ltd., etc. At present, there are seven Pancreatic Kininogenase manufacturers in China. Changzhou Qianhong Bio-pharma Co., Ltd.'s Pancreatic Kininogenase (trade name: Yikai) takes up about 90% market share by sales value.

It is expected that as the incidence of cardiovascular and cerebrovascular diseases continues to increase, China's Pancreatic Kininogenase market will still have some growth potential in the next few years.

Topics Covered:

  • Situation of cardiovascular and cerebrovascular diseases in China
  • Status of China's Pancreatic Kininogenase market
  • Competition on China's Pancreatic Kininogenase market
  • Factors influencing the development of China's Pancreatic Kininogenase market
  • Prospect of China's Pancreatic Kininogenase market

Table of Contents

1 Relevant Concepts of Pancreatic Kininogenase

  • 1.1 Indications for Pancreatic Kininogenase
  • 1.2 Development of Pancreatic Kininogenase in China
  • 1.3 Government Approval of Pancreatic Kininogenase in China

2 Sales of Pancreatic Kininogenase in China, 2013-2017

  • 2.1 Sales Value of Pancreatic Kininogenase
    • 2.1.1 Overall Sales Value
    • 2.1.2 Sales Value by Region
  • 2.2 Sales Volume of Pancreatic Kininogenase
    • 2.2.1 Overall Sales Volume
    • 2.2.2 Sales Volume by Region
  • 2.3 Sales of Pancreatic Kininogenase by Dosage Form in China, 2013-2017
    • 2.3.1 Pancreatic Kininogenase Injections
    • 2.3.2 Pancreatic Kininogenase Tablets

3 Analysis on Major Pancreatic Kininogenase Manufacturers in China, 2013-2017

  • 3.1 Analysis on Market Share of Major Pancreatic Kininogenase Manufacturers in China
    • 3.1.1 Market Share by Sales Value
    • 3.1.2 Market Share by Sales Volume
  • 3.2 Shanghai Livzon Pharmaceutical Co., Ltd.
    • 3.2.1 Enterprise Profile
    • 3.2.2 Sales of Shanghai Livzon Pharmaceutical Co., Ltd.'s Pancreatic Kininogenase in China
  • 3.3 Sichuan Shunsheng Pharmaceutical Co., Ltd.
    • 3.3.1 Enterprise Profile
    • 3.3.2 Sales of Sichuan Shunsheng Pharmaceutical Co., Ltd.'s Pancreatic Kininogenase in China
  • 3.4 Changzhou Qianhong Bio-pharma Co., Ltd.
  • 3.5 Chengdu Tongde Pharmaceutical Co., Ltd.
  • 3.6 Henan Livu Pharmacy Co., Ltd.

4 Prices of Pancreatic Kininogenase in China, 2017-2018

  • 4.1 Shanghai Livzon Pharmaceutical Co., Ltd. (Guangle)
  • 4.2 Sichuan Shunsheng Pharmaceutical Co., Ltd. (Dashun)
  • 4.3 Changzhou Qianhong Bio-pharma Co., Ltd. (Yikai)
  • 4.4 Chengdu Tongde Pharmaceutical Co., Ltd. (Tongde)
  • 4.5 Henan Livu Pharmaceutical Co., Ltd. (Duomeile)

5 Prospect of China's Pancreatic Kininogenase Market, 2018-2022

  • 5.1 Factors Influencing Development Pancreatic Kininogenase Market
  • 5.2 Forecast on Market Size
  • 5.3 Forecast on Market Trend

Selected Charts

  • Chart Government Approval of Pancreatic Kininogenase in China
  • Chart Sales Value of Pancreatic Kininogenase in China, 2013-2017
  • Chart Sales Value of Pancreatic Kininogenase in Parts of China, 2013-2017
  • Chart Sales Volume of Pancreatic Kininogenase in China, 2013-2017
  • Chart Sales Volume of Pancreatic Kininogenase in Parts of China, 2013-2017
  • Chart Sales Value of Pancreatic Kininogenase Injections in China, 2013-2017
  • Chart Sales Volume of Pancreatic Kininogenase Injections in China, 2013-2017
  • Chart Sales Value of Pancreatic Kininogenase Tablets in China, 2013-2017
  • Chart Market Share of Top 5 Pancreatic Kininogenase Manufacturers by Sales Value in China, 2013-2017
  • Chart Market Share of Top 5 Pancreatic Kininogenase Manufacturers by Sales Volume in China, 2013-2017
  • Chart Sales Value of Shanghai Livzon Pharmaceutical Co., Ltd.'s Pancreatic Kininogenase, 2013-2017
  • Chart Sales Volume of Shanghai Livzon Pharmaceutical Co., Ltd.'s Pancreatic Kininogenase, 2013-2017
  • Chart Sales Value of Sichuan Shunsheng Pharmaceutical Co., Ltd.'s Pancreatic Kininogenase, 2013-2017
  • Chart Sales Value of Changzhou Qianhong Bio-pharma Co., Ltd.'s Pancreatic Kininogenase, 2013-2017
  • Chart Sales Value of Chengdu Tongde Pharmaceutical Co., Ltd.'s Pancreatic Kininogenase, 2013-2017
  • Chart Prices of Shanghai Livzon Pharmaceutical Co., Ltd.'s Pancreatic Kininogenase in Parts of China, 2017-2018
  • Chart Prices of Sichuan Shunsheng Pharmaceutical Co., Ltd.'s Pancreatic Kininogenase in Parts of China, 2017-2018
  • Chart Prices of Changzhou Qianhong Bio-pharma Co., Ltd.'s Pancreatic Kininogenase in Parts of China, 2017-2018
  • Chart Forecast on Sales Value of Pancreatic Kininogenase in China, 2018-2022
Back to Top